← Leaderboards
Mikhail M Dikov
Vanderbilt University
$4,391,433
Attributed
$7,431,167
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $741.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,431,167 · 4
By mechanism
R01$7,431,167 · 4
Top collaborators
- David P Carbone10 shared
- Igor Feoktistov5 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Igor Feoktistov$5,033,233
- Raymond Nelson Dubois$22,706,669
- Caroline Nebhan$258,460
Others in their field
Top investigators on “Dendritic Cells”
- Barton F Haynes · Duke University$112,608,041
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- James C. Paulson · Scripps Research Institute$41,568,802
- Ulrich H Von Andrian · Harvard Medical School$32,521,007
- Donald L Morton · John Wayne Cancer Institute$29,042,629
Research focus
Dendritic CellsCellsMediatingImmuneTumorMalignant NeoplasmsImmunotherapySignal TransductionImmunityTumor ImmunityTumor GrowthRegulationT-LymphocyteGeneticCell Differentiation ProcessCancer PatientAnimalsHematopoieticPreclinical StudyReceptorEvaluationExtracellularNon-Small-Cell Lung CarcinomaDesign
Grant awards (20)
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$741,840
R01 · FY2025 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$704,749
R01 · FY2024 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$380,473
R01 · FY2023 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$559,834
R01 · FY2022 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$577,069
R01 · FY2021 · CA
Notch ligands in regulation of anti-cancer immunity$314,259
R01 · FY2017 · CA
Notch ligands in regulation of anti-cancer immunity$314,259
R01 · FY2016 · CA
Notch ligands in regulation of anti-cancer immunity$314,259
R01 · FY2015 · CA
Adenosine in Tumor-Host Interaction$342,642
R01 · FY2014 · CA
Notch ligands in regulation of anti-cancer immunity$304,831
R01 · FY2014 · CA
Adenosine in Tumor-Host Interaction$332,045
R01 · FY2013 · CA
Notch ligands in regulation of anti-cancer immunity$327,050
R01 · FY2013 · CA
Adenosine in Tumor-Host Interaction$353,239
R01 · FY2012 · CA · contact PI
Adenosine in Tumor-Host Interaction$352,106
R01 · FY2011 · CA · contact PI
Adenosine in Tumor-Host Interaction$160,813
R01 · FY2010 · CA · contact PI
Vascular Endothelial Growth Factor in Hematopoiesis in Cancer$264,158
R01 · FY2008 · CA · contact PI
Vascular Endothelial Growth Factor in Hematopoiesis in Cancer$264,158
R01 · FY2007 · CA · contact PI
The Role of VEGF in Hematopoiesis in Cancer$272,048
R01 · FY2006 · CA · contact PI
The Role of VEGF in Hematopoiesis in Cancer$278,595
R01 · FY2005 · CA
VEGF in Hematopoiesis in Cancer$272,740
R01 · FY2004 · CA